Debén Méndez, BeatrizRodríguez Roldán, MartaGarrido Botella, María IsabelGonzález Cantero, MercedesTeja, MacarenaRosa, Alonso laRosel Aller, RafaelBelinchón Olmeda, BelénMiralles Olivar, LaraDuque Santana, VíctorEt. al.2026-10-052026-10-052026Debén Méndez, B., Rodríguez Roldán, M., Garrido Botella, M. I., González Cantero, M., Teja Ubach, M., La Rosa, A., Rosel Aller, R., Belinchón Olmeda, B., Miralles Olivar, L., Enriquez, L. A. G., De Manso De Lema, A., Duque Santana, V., Díez Sebastián, J., & Gonzalez Del Portillo, E. (2026). The role of SBRT as an ablative treatment in oligometastatic patients. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04462-x1699-048X1699-3055https://hdl.handle.net/11268/17459Extracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios.engMedicinaTerapia por LáserRadiocirugiaAnálisis de Supervivenciajournal article10.1007/s12094-026-04462-xrestricted accessCáncerTratamiento médicoInvestigación médicaGoal 3: Ensure healthy lives and promote well-being for all at all ages